Can Lupus Cause Fatty Liver Disease?

Lupus can cause or contribute to fatty liver disease through several overlapping mechanisms, making liver health an important consideration in lupus care. Systemic lupus erythematosus (SLE) is associated with metabolic disturbances, chronic inflammation, and the use of corticosteroids, all of which can promote fat accumulation in the liver. Autoimmune hepatitis may also occur alongside lupus, adding further complexity. Understanding the relationship between lupus and liver disease helps ensure timely monitoring, accurate diagnosis, and appropriate management within NHS care pathways.

Can lupus cause fatty liver disease?

Lupus can contribute to fatty liver disease via corticosteroid use, insulin resistance, dyslipidaemia, and chronic inflammation, though not everyone with SLE will develop liver disease.

Lupus can contribute to liver problems, including fatty liver disease, though the relationship is complex and not always direct. Systemic lupus erythematosus (SLE) is a chronic autoimmune condition in which the immune system attacks the body's own tissues, and the liver can be affected in several ways. Liver abnormalities are recognised as a feature of SLE in a substantial minority of people with the condition, though reported prevalence varies across studies depending on the criteria used and the population examined.

Fatty liver disease, known medically as hepatic steatosis, involves the accumulation of fat within liver cells. In people with lupus, this can arise through several overlapping mechanisms. Corticosteroids such as prednisolone, which are commonly used to manage lupus flares, are well recognised as a cause of drug-induced fatty liver.^[9] Prolonged or high-dose steroid use can promote fat deposition in the liver independently of diet or metabolic factors.

Beyond medication effects, lupus itself is associated with metabolic disturbances, including insulin resistance and dyslipidaemia, both of which are established risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD).^[2] Chronic systemic inflammation, a hallmark of lupus, may also impair normal liver metabolism.

Additionally, autoimmune hepatitis can occur in the context of lupus, sometimes referred to informally as lupus hepatitis. This is a distinct form of immune-mediated liver inflammation and differs from fatty change, though the two can coexist. It is important to note that autoimmune hepatitis occurring alongside SLE shares features with, but is not identical to, classical autoimmune hepatitis, and specialist assessment is needed to distinguish them.

Primary biliary cholangitis (PBC) is also more common in people with autoimmune conditions generally, and there are published reports of its co-occurrence with SLE, though the association is less well characterised than with other autoimmune diseases and should not be overstated.^[5][6]

Not everyone with lupus will develop liver disease, and many liver abnormalities in lupus are mild and reversible. However, given the multiple potential contributors, liver health warrants monitoring as part of routine lupus care.

What are the signs of liver problems in people with lupus?

Liver problems in lupus often present with fatigue, upper right abdominal discomfort, and raised liver enzymes on blood tests; jaundice, dark urine, or abdominal swelling indicate more significant involvement.

Liver problems in people with lupus often produce subtle or non-specific symptoms, which can make them easy to overlook or attribute to lupus itself. The most commonly reported symptoms include fatigue, a feeling of fullness or discomfort in the upper right abdomen, mild nausea, and a general sense of being unwell. Because fatigue is already a dominant feature of lupus, liver-related tiredness may not immediately raise concern.

In more significant liver involvement, people may notice:

• Jaundice: yellowing of the skin or whites of the eyes, indicating impaired bilirubin processing

• Dark urine or pale stools: further signs of disrupted liver function

• Abdominal swelling: which may suggest fluid accumulation (ascites) in advanced disease

• Itching (pruritus): caused by bile salt accumulation under the skin

• Easy bruising or prolonged bleeding: reflecting reduced production of clotting factors

Blood tests frequently reveal liver abnormalities before symptoms appear. Raised levels of liver enzymes, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), are common findings in lupus and may indicate hepatocellular inflammation or damage. Elevated alkaline phosphatase (ALP) can suggest bile duct involvement, though ALP can also be raised from non-hepatic sources such as bone; measuring gamma-glutamyl transferase (GGT) alongside ALP helps confirm a hepatic origin, in line with UK guidance.

It is worth noting that some lupus medications, including methotrexate and azathioprine, can cause liver enzyme elevations. Hydroxychloroquine is occasionally associated with liver enzyme changes, but clinically significant hepatotoxicity with this medicine is rare; any such association should be interpreted in the context of the full clinical picture and, where relevant, the medicine's summary of product characteristics.^[7][8] Distinguishing drug-induced changes from disease-related liver involvement requires careful clinical assessment.

Anyone with lupus who develops new jaundice, confusion, vomiting of blood or black tarry stools, or severe pain in the upper right abdomen with fever should seek urgent medical attention the same day, either by contacting their GP, calling NHS 111, or attending an emergency department as appropriate. New or worsening abdominal symptoms, unexplained jaundice, or significant changes in general health should not be assumed to be part of the usual lupus pattern and should be assessed promptly.

Diagnosing fatty liver disease alongside lupus in the UK

Diagnosis involves liver blood tests, abdominal ultrasound, and non-invasive fibrosis scoring using the FIB-4 index, in line with NICE NG49 and BSG guidance, with biopsy reserved for uncertain cases.

Diagnosing fatty liver disease in someone with lupus requires a systematic approach that accounts for the multiple potential causes of liver abnormality in this population. In UK clinical practice, initial assessment typically involves blood tests to evaluate liver function, including ALT, AST, ALP, GGT, bilirubin, and albumin. These are often performed as part of routine lupus monitoring, meaning abnormalities may be detected incidentally.

Where liver blood tests are abnormal, a standard initial aetiology screen in primary care, consistent with BSG and BASL guidance on abnormal liver blood tests, would typically include assessment of alcohol intake, a medication review, viral hepatitis B and C serology, autoimmune markers (including antinuclear antibody, anti-smooth muscle antibody, and anti-mitochondrial antibody), immunoglobulins, ferritin and iron studies, and thyroid function. Coeliac serology may also be considered. In the context of lupus, interpreting autoimmune markers requires particular care, as SLE itself can produce positive autoantibody results.

Ultrasound of the abdomen is the most widely used first-line imaging investigation for suspected fatty liver disease. It is non-invasive, widely available on the NHS, and can identify increased echogenicity of the liver, which is characteristic of hepatic steatosis. However, ultrasound has limitations in detecting mild fat accumulation and cannot reliably quantify the degree of fibrosis.

Where more detailed assessment is needed, NICE guidance (NG49) supports the use of non-invasive fibrosis scoring tools. The FIB-4 index, calculated from age, ALT, AST, and platelet count, is recommended by NICE as an initial step to stratify fibrosis risk. NICE NG49 provides specific cut-off values and age-adjusted thresholds to guide referral decisions; clinicians should refer to the current published guidance for these figures, as they inform whether a patient can be managed in primary care or requires secondary care assessment. The NAFLD Fibrosis Score is an alternative non-invasive tool also referenced in NICE guidance. Enhanced liver fibrosis (ELF) testing and transient elastography (FibroScan) may be used in secondary care to assess liver stiffness and guide further management.

In people with lupus, distinguishing between steroid-induced fatty liver, MASLD, autoimmune hepatitis occurring in the context of lupus, and primary biliary cholangitis is clinically important, as each has different management implications. Liver biopsy may occasionally be required when the diagnosis remains uncertain after non-invasive testing, though this is reserved for cases where the result would meaningfully change management. Rheumatology and hepatology teams often collaborate in these assessments.

What treatments are available for lupus-related liver conditions?

Treatment depends on the underlying cause; steroid dose reduction, steroid-sparing agents, and metabolic risk factor management are key strategies, with no pharmacological treatment currently licensed specifically for MASLD in the UK.

Treatment for liver conditions in people with lupus depends on the underlying cause identified through investigation, and there is no single universal approach. Where corticosteroid use is identified as the primary driver of fatty liver, the treating rheumatologist may consider whether the steroid dose can be reduced or whether steroid-sparing agents can be optimised to allow this. Azathioprine and mycophenolate mofetil are immunosuppressants used in this context. Hydroxychloroquine, which is better described as an antimalarial and immunomodulatory agent rather than an immunosuppressant, is also used in lupus management and may form part of an overall treatment strategy. Dose reduction of corticosteroids must always be balanced carefully against the risk of lupus flare.

For autoimmune hepatitis occurring in the context of lupus, corticosteroids paradoxically remain a mainstay of treatment, often in combination with azathioprine, mirroring the approach used in primary autoimmune hepatitis.^[12][13] Response to treatment is monitored through serial liver function tests and, where appropriate, repeat imaging.

For MASLD occurring alongside lupus, there is currently no pharmacological treatment licensed specifically for hepatic steatosis in the UK.^[3][4] This is an active area of research and the licensing landscape may evolve; clinicians should refer to current MHRA and NICE guidance for the most up-to-date position. Management focuses on addressing modifiable metabolic risk factors, including weight management, blood glucose control in those with diabetes or insulin resistance, and lipid management. It is worth noting that statins are generally considered safe and appropriate to use in people with MASLD when clinically indicated for cardiovascular risk reduction, and concerns about statin-related liver injury in this group should not lead to therapeutic inertia; this is consistent with BSG and BASL guidance.^[1][2]

NICE guidance on NAFLD (NG49) remains a relevant reference point for the investigation and management pathway, though clinicians will adapt this to the specific context of lupus.

People with lupus who are found to have significant liver fibrosis or cirrhosis will typically be referred to hepatology for specialist management, which may include surveillance for complications such as portal hypertension and hepatocellular carcinoma. Suspected adverse drug reactions affecting the liver, including drug-induced liver injury, can be reported to the MHRA via the Yellow Card scheme (available at yellowcard.mhra.gov.uk), which accepts reports from both patients and healthcare professionals.

Managing both conditions: lifestyle and NHS support options

A Mediterranean-style diet, regular moderate exercise, alcohol reduction, and weight management are central to improving liver health in people with lupus, supported by NHS services and coordinated specialist care.

Managing lupus and fatty liver disease together requires a coordinated approach that addresses both conditions simultaneously, rather than treating each in isolation. Lifestyle modification is central to reducing liver fat and improving metabolic health, and many of the same measures that benefit liver disease also support lupus management more broadly.

Key lifestyle strategies include:

• Dietary adjustment: a balanced diet low in refined carbohydrates, saturated fats, and ultra-processed foods supports liver health. The NHS Eatwell Guide provides a practical framework. Some evidence supports a Mediterranean-style dietary pattern for reducing liver fat and systemic inflammation.

• Physical activity: regular moderate-intensity exercise, such as brisk walking, swimming, or cycling, can reduce hepatic fat and improve insulin sensitivity. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, though people with lupus should pace activity according to their current disease activity and fatigue levels.^[14][15]

• Alcohol: people with any form of liver disease are advised to seek specialist advice on alcohol intake, as alcohol compounds liver injury regardless of the underlying cause. For those without established liver disease, the UK Chief Medical Officers' low-risk drinking guidelines recommend keeping intake to no more than 14 units per week, spread across several days, with regular alcohol-free days.^[16]

• Weight management: even modest weight loss of 5 to 10 per cent of body weight has been shown to reduce liver fat in people with MASLD, as noted in NICE NG49.^[2]

Within the NHS, people with lupus are typically managed by a rheumatologist, and liver concerns may prompt onward referral to hepatology or gastroenterology. GP practices can provide support with lifestyle change through social prescribing and referral to NHS weight management services. Information on NHS weight management support is available through NHS.uk.

For those exploring weight management support as part of their overall care, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options can be discussed.

Open communication between rheumatology, hepatology, and primary care teams is essential to ensure that treatment decisions for lupus do not inadvertently worsen liver health, and vice versa.

Scientific References

1. Guidelines on the management of abnormal liver blood tests.
2. Metabolic dysfunction-associated steatotic liver disease (NG49).
3. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
4. Non-alcoholic fatty liver disease (NAFLD).
5. Primary biliary cholangitis.
6. SLE and PBC co-occurrence: a systematic review and meta-analysis.
7. Hydroxychloroquine sulfate 200 mg film-coated tablets – Summary of Product Characteristics.
8. Hydroxychloroquine sulfate – BNF.
9. Corticosteroid dose increase is a risk factor for nonalcoholic fatty liver disease and contralateral osteonecrosis of the femoral head: a case report.
10. Shared pathogenic mechanisms between systemic lupus erythematosus and autoimmune hepatitis: A unified view of autoimmune convergence.
11. Treatment of systemic lupus erythematosus overlap syndrome with autoimmune hepatitis using a combination of glucocorticoids and immunosuppressive agents: Case report.
12. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis.
13. Second-line tacrolimus and mycophenolate mofetil in difficult-to-treat autoimmune hepatitis.
14. Physical activity guidelines: UK Chief Medical Officers' report.
15. Physical activity guidelines for adults aged 19 to 64.
16. Alcohol consumption: advice on low risk drinking.

Frequently Asked Questions